How to buy Zimmer Biomet shares

Own Zimmer Biomet shares in just a few minutes.

Zimmer Biomet logo

We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!

Zimmer Biomet Holdings, Inc (ZBH) is a leading medical devices business with stocks listed in the US. It opened the day at US$163.8 after a previous close of US$163.48. During the day the price has varied from a low of USD162.78 to a high of USD167.15. The latest price was USD166.38 (25 minute delay). Zimmer Biomet is listed on the NYSE. All prices are listed in US Dollars.

How to buy shares in Zimmer Biomet

  1. Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Zimmer Biomet. Find the share by name or ticker symbol: ZBH. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Zimmer Biomet reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of US$159.13, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Zimmer Biomet, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Zimmer Biomet. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Zimmer Biomet share price

Use our graph to track the performance of ZBH stocks over time.

Zimmer Biomet shares at a glance

Information last updated 2021-06-22.
OpenUS$163.8
HighUS$167.15
LowUS$162.78
CloseUS$166.38
Previous closeUS$163.48
Change US$2.9
Change % 1.7739%
Volume 1,960,559
Information last updated 2021-06-17.
52-week rangeUS$111.2211 - US$180.36
50-day moving average US$166.5335
200-day moving average US$160.806
Target priceUS$191.58
PE ratio 57.9714
Dividend yield US$0.96 (0.61%)
Earnings per share (TTM) US$2.726

Compare share trading platforms to buy stock

Name Product Standard brokerage for US shares Inactivity fee Currency conversion fee Markets
eToro (US, EU stock trading)
US$0
US$10 per month if there’s been no login for 12 months
0.50%
Global shares, US shares, ETFs
Zero brokerage share trading on US stocks with trades as low as $50.
Join the world’s biggest social trading network when you trade stocks, commodities and currencies from the one account.
IG Share Trading
Finder Award
IG Share Trading
US$0
$50 per quarter if you make fewer than three trades in that period
0.70%
ASX shares, Global shares
$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares.
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, plus get access to 24-hour customer support.
Saxo Capital Markets (Classic account)
US$9.9
No
0.75%
ASX shares, Global shares, Forex, CFDs, Margin trading, Options trading, ETFs
Acess 19,000+ stocks on 37 exchanges worldwide
Low fees for Australian and global share trading, no inactivity fees, low currency conversion fee and optimised for mobile.
CMC Markets Stockbroking
US$0
No
0.60%
ASX shares, Global shares, mFunds, ETFs
$0 brokerage on global shares including US, UK and Japan markets.
Trade up to 9,000 products, including shares, ETFs and managed funds, plus access up to 15 major global and Australian stock exchanges.
loading

Compare up to 4 providers

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy Zimmer Biomet stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Zimmer Biomet price performance over time

Historical closes compared with the last close of $166.38

1 week (2021-06-16) 5.28%
1 month (2021-05-21) -0.56%
3 months (2021-03-23) 6.56%
6 months (2020-12-23) 11.68%
1 year (2020-06-23) 32.09%
2 years (2019-06-21) 40.65%
3 years (2018-06-22) 48.87%
5 years (2016-06-23) 37.60%

Is Zimmer Biomet under- or over-valued?

Valuing Zimmer Biomet stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Zimmer Biomet's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Zimmer Biomet's P/E ratio

Zimmer Biomet's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 58x. In other words, Zimmer Biomet shares trade at around 58x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Zimmer Biomet's PEG ratio

Zimmer Biomet's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.5913. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Zimmer Biomet's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Zimmer Biomet's EBITDA

Zimmer Biomet's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$2 billion.

The EBITDA is a measure of a Zimmer Biomet's overall financial performance and is widely used to measure a its profitability.

Zimmer Biomet financials

Revenue TTM US$7.1 billion
Operating margin TTM 13.35%
Gross profit TTM US$4.9 billion
Return on assets TTM 2.39%
Return on equity TTM 4.68%
Profit margin 8.01%
Book value 59.717
Market capitalisation US$32.9 billion

TTM: trailing 12 months

Shorting Zimmer Biomet shares

There are currently 1.9 million Zimmer Biomet shares held short by investors – that's known as Zimmer Biomet's "short interest". This figure is 17.9% down from 2.3 million last month.

There are a few different ways that this level of interest in shorting Zimmer Biomet shares can be evaluated.

Zimmer Biomet's "short interest ratio" (SIR)

Zimmer Biomet's "short interest ratio" (SIR) is the quantity of Zimmer Biomet shares currently shorted divided by the average quantity of Zimmer Biomet shares traded daily (recently around 1.1 million). Zimmer Biomet's SIR currently stands at 1.77. In other words for every 100,000 Zimmer Biomet shares traded daily on the market, roughly 1770 shares are currently held short.

However Zimmer Biomet's short interest can also be evaluated against the total number of Zimmer Biomet shares, or, against the total number of tradable Zimmer Biomet shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Zimmer Biomet's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Zimmer Biomet shares in existence, roughly 10 shares are currently held short) or 0.009% of the tradable shares (for every 100,000 tradable Zimmer Biomet shares, roughly 9 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Zimmer Biomet.

Find out more about how you can short Zimmer Biomet stock.

Zimmer Biomet's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Zimmer Biomet.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Zimmer Biomet's total ESG risk score

Total ESG risk: 40.16

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Zimmer Biomet's overall score of 40.16 (as at 12/31/2018) is pretty weak – landing it in it in the 77th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Zimmer Biomet is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Zimmer Biomet's environmental score

Environmental score: 9.29/100

Zimmer Biomet's environmental score of 9.29 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that Zimmer Biomet is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Zimmer Biomet's social score

Social score: 23.4/100

Zimmer Biomet's social score of 23.4 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that Zimmer Biomet is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Zimmer Biomet's governance score

Governance score: 16.46/100

Zimmer Biomet's governance score puts it squarely in the 9th percentile of companies rated in the same sector. That could suggest that Zimmer Biomet is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Zimmer Biomet's controversy score

Controversy score: 2/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Zimmer Biomet scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Zimmer Biomet has, for the most part, managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Zimmer Biomet Holdings, Inc was last rated for ESG on: 2019-01-01.

Total ESG score 40.16
Total ESG percentile 77.24
Environmental score 9.29
Environmental score percentile 9
Social score 23.4
Social score percentile 9
Governance score 16.46
Governance score percentile 9
Level of controversy 2

Zimmer Biomet share dividends

17%

Dividend payout ratio: 16.9% of net profits

Recently Zimmer Biomet has paid out, on average, around 16.9% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.61% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Zimmer Biomet shareholders could enjoy a 0.61% return on their shares, in the form of dividend payments. In Zimmer Biomet's case, that would currently equate to about $0.96 per share.

While Zimmer Biomet's payout ratio might seem low, this can signify that Zimmer Biomet is investing more in its future growth.

Zimmer Biomet's most recent dividend payout was on 29 July 2021. The latest dividend was paid out to all shareholders who bought their shares by 24 June 2021 (the "ex-dividend date").

Zimmer Biomet share price volatility

Over the last 12 months, Zimmer Biomet's shares have ranged in value from as little as US$111.2211 up to US$180.36. A popular way to gauge a stock's volatility is its "beta".

ZBH.US volatility(beta: 1.36)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Zimmer Biomet's is 1.3554. This would suggest that Zimmer Biomet's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Zimmer Biomet overview

Zimmer Biomet Holdings, Inc., together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company provides orthopaedic reconstructive products, such as knee and hip replacement products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as surgical, bone cement, and office-based technology products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com.au:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com.au is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site
Not sure what platform to go with?
Take this quick quiz to find the right share trading platform